ZKB/PUT/ELI LILLY & CO/770/0.01/28.06.24 | Real-time Bid/Ask 15:31:16 23/05/2024 BST | ||
| 0.1 CHF / 0.11 CHF | -19.23% |
|
| Current month | -58.06% | ||
| 1 month | -76.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 0.13 | -40.91% |
| 17/05/24 | 0.22 | +4.76% |
| 15/05/24 | 0.21 | -36.36% |
| 14/05/24 | 0.33 | -2.94% |
Delayed Quote Swiss Exchange
Last update May 21, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | ZKB |
| LLYFAZ | |
| ISIN | CH1305143559 |
| Date issued | 08/03/2024 |
| Strike | 770 $ |
| Maturity | 28/06/2024 (36 Days) |
| Parity | 100 : 1 |
| Emission price | 0.45 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.6 CHF |
|---|---|
| Lowest since issue | 0.13 CHF |
| Spread | 0.01 CHF |
| Spread % | 8.33% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- LLYFAZ Warrant
